Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Chemomab Therapeutics (CMMB) EPS (Weighted Average and Diluted) (2021 - 2025)

Chemomab Therapeutics posted quarterly EPS (Weighted Average and Diluted) of -$0.03 for Q4 2025, up 54.5% year-on-year from -$0.02 in Q4 2024, and up 54.5% on a QoQ basis from -$0.07 in Q4 2024.

Chemomab Therapeutics (CMMB) has 5 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.03 in Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 54.5% year-over-year to -$0.03; the trailing twelve-month figure through Dec 2025 stood at -$0.03 (up 54.5% YoY), and the FY2025 full-year result was $0.02, down 53.85% from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 stood at -$0.03, up from -$0.07 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.04 in Q1 2023 and bottomed at -$0.07 in Q4 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.02 (2021), against an average of $0.01.
  • The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) soared 169.23%; it then plunged 577.46% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.02 in 2021, then soared by 63.64% to $0.04 in 2022, then tumbled by 59.61% to $0.01 in 2023, then slumped by 577.46% to -$0.07 in 2024, then surged by 54.5% to -$0.03 in 2025.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$0.03 (Q4 2025), -$0.07 (Q4 2024), and $0.01 (Q2 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -4.43
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.02
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.51
10 Chemomab Therapeutics 959.23 Mn 948.86 Mn - -0.03

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -0.03
Dec 31, 2024 -0.07
Jun 30, 2024 0.01
Dec 31, 2023 0.01
Jun 30, 2023 0.04
Mar 31, 2023 0.04
Dec 31, 2022 0.04
Sep 30, 2022 0.04
Jun 30, 2022 0.03
Mar 31, 2022 0.02
Dec 31, 2021 0.02
Sep 30, 2021 0.01
Jun 30, 2021 0.01